126 related articles for article (PubMed ID: 32152877)
1. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
Koutake Y; Taniguchi J; Yasumori N; Nagaishi H; Eto T; Nakashima K; Fukazawa M; Hayashi T
Int J Hematol; 2020 Jun; 111(6):826-832. PubMed ID: 32152877
[TBL] [Abstract][Full Text] [Related]
2. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
Yin OQ; Giles FJ; Baccarani M; le Coutre P; Chiparus O; Gallagher N; Saglio G; Hughes TP; Hochhaus A; Kantarjian HM; Larson RA
Cancer Chemother Pharmacol; 2012 Aug; 70(2):345-50. PubMed ID: 22623211
[TBL] [Abstract][Full Text] [Related]
3. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N; Miura M; Niioka T; Sawada K
Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
6. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2018 Jul; 124(13):2740-2747. PubMed ID: 29723397
[TBL] [Abstract][Full Text] [Related]
7. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
9. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
Imagawa J; Tanaka H; Okada M; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Morita S; Sakamoto J; Kimura S;
Lancet Haematol; 2015 Dec; 2(12):e528-35. PubMed ID: 26686407
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.
Chen LF; Yuan GL; Zhong ZD; Zou P; Li DJ; Bao Y; Ren HB; Meng L; Li WM
Curr Med Sci; 2018 Dec; 38(6):1005-1011. PubMed ID: 30536062
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase].
Chen YL; Wang L; Yan GL; Yang ZZ; Huang ZP; Zhang YS; Zhao Z; Wan CC; Bao Y; Xiang H; Yin H; Chen LF; Xiong YY; Meng L; Li WM
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):98-104. PubMed ID: 30831623
[No Abstract] [Full Text] [Related]
13. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
14. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
Kimura S; Imagawa J; Murai K; Hino M; Kitawaki T; Okada M; Tanaka H; Shindo M; Kumagai T; Ikezoe T; Uoshima N; Sato T; Watanabe R; Kowata S; Hayakawa M; Hosoki T; Ikeda K; Kobayashi T; Kakinoki Y; Nishimoto T; Takezako N; Shibayama H; Takaori-Kondo A; Nakamae H; Kawaguchi A; Ureshino H; Sakamoto J; Ishida Y;
Lancet Haematol; 2020 Mar; 7(3):e218-e225. PubMed ID: 31978329
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.
Iriyama N; Ohashi K; Hashino S; Kimura S; Nakaseko C; Takano H; Hino M; Uchiyama M; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Intern Med; 2018 Jan; 57(1):17-23. PubMed ID: 29033428
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
19. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
20. Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
Larfors G; Andersson P; Jesson G; Liljebris C; Brisander M; Lennernäs H; Stenke L
Eur J Haematol; 2023 Oct; 111(4):644-654. PubMed ID: 37503797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]